Monitor 2026 revenue recognition from the $49.5 million in purchase orders and track commercial deployment progress. The stock may react positively if the company converts these orders into actual revenue, but remains high-risk given current losses and small market cap.
Price Chart
Executive Summary
Inspira Technologies reported minimal 2025 revenue of $289,000 and a net loss of $13.22 million, but secured $49.5 million in binding purchase orders expected to convert to revenue in 2026. The company also raised $4.75 million in gross proceeds post-year-end, ensuring Nasdaq compliance. Clinical deployments and commercial traction for its ART100 system are progressing, though financials remain weak.
Key Facts
- 2025 revenue was $289,000, up from $0 in 2024
- Net loss widened to $13.22 million in 2025 from $11.053 million in 2024
- Secured binding purchase orders totaling $49.5 million, with revenue expected in 2026
- Cash and cash equivalents decreased to $3.159 million as of December 31, 2025, from $5.779 million in 2024
- Completed a registered direct offering post-year-end, generating gross proceeds of $4.75 million
- Company believes it now satisfies Nasdaq's $2.5 million shareholders' equity requirement
- ART100 system deployed at multiple leading U.S. medical centers, including use in lung transplant cases
- Appointed former Johnson & Johnson executive as VP of Global Sales
- Terminated non-binding term sheet with Bio-View Ltd. for acquisition of liquid biopsy business
Financial Impact
Revenue expected to increase significantly in 2026 from $49.5 million in purchase orders, though 2025 revenue was minimal at $289,000. Net loss increased to $13.22 million. Cash position improved by $4.75 million from offering.
Risk Factors
- High cash burn with net loss increasing while revenue remains minimal
- Revenue from $49.5 million in purchase orders is not yet recognized and dependent on procurement processes
- Small market cap ($5M) makes the stock highly volatile and speculative
- Continued reliance on capital raises for survival
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001185185-26-001077 |
| Document: iinn6k032626.htm | 0001185185-26-001077 |
| Document: 0001185185-26-001077-index-headers.html | 0001185185-26-001077 |
| Document: 0001185185-26-001077-index.html | 0001185185-26-001077 |
| Document: 0001185185-26-001077.txt | 0001185185-26-001077 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 19w ago | 6-K | $0.1420 $0.1200 | ▼ −15.49% | ▼ −16.48% | — |
May 18, 2026 19w ago | 6-K | $0.0830 $0.1310 | ▲ +57.83% | ▲ +56.25% | — |
Apr 16, 2026 24w ago | 6-K | $0.1100 $0.0690 | ▼ −37.27% | ▼ −43.09% | — |
Apr 16, 2026 24w ago | 6-K | $0.1100 $0.0690 | ▼ −37.27% | ▼ −43.09% | — |
Apr 15, 2026 24w ago | 6-K | $0.1100 $0.0690 | ▼ −37.27% | ▼ −43.09% | — |
Apr 14, 2026 24w ago | 6-K | $0.0720 $0.0690 | ▼ −4.17% | ▼ −10.46% | — |
Apr 13, 2026 24w ago | 6-K | $0.0600 $0.0690 | ▲ +15.00% | ▲ +7.27% | — |
Apr 6, 2026 25w ago | 6-K | $0.1000 $0.0680 | ▼ −32.00% | ▼ −40.98% | — |
Apr 6, 2026 25w ago | 6-K | $0.1000 $0.0680 | ▼ −32.00% | ▼ −40.98% | — |
Mar 31, 2026 26w ago | 6-K | $0.0800 $0.0690 | ▼ −13.75% | ▼ −23.17% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access